Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
20 Junho 2024 - 7:05AM
Business Wire
Following a successful limited market
release, the Omnipod 5 Automated Insulin Delivery System (Omnipod
5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre
2 Plus in these countries
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today announced that Omnipod 5, compatible with
both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose
monitor (CGM) sensors, is now fully available in the U.K. and the
Netherlands for individuals aged two years and older with type 1
diabetes. Omnipod 5 is the first and only tubeless automated
insulin delivery (AID) system integrated with both of the leading
CGM sensor brands, Dexcom and Abbott FreeStyle Libre.
“Expanding global access to Omnipod 5 is one of our top
priorities. With the exciting, updated compatibility with both the
Abbott FreeStyle Libre 2 Plus and the Dexcom G6 sensors, thousands
more people with diabetes can enjoy the incredible freedom of
tubeless, automated insulin delivery without having to change their
CGM sensor brand. This is a game-changer for diabetes management,”
said Patrick Crannell, Insulet Senior Vice President and
International General Manager.
Omnipod 5 is the first tubeless, waterproof1 AID system with
proactive glucose control. The System is designed to be
customer-centric and aims to deliver exceptional ease of use. It
has demonstrated strong clinical results including lower A1c and
improved time in range, while maintaining low time in
hypoglycemia.2,3
“Pod therapy is great because it is tubeless, and easy to use,”
said Dion Screever, an 18-year-old student from the Netherlands.
“When I started on Omnipod 5, I immediately noticed that my blood
sugar was in range with much less effort from me, because of the
automated insulin delivery technology. As someone who has lived
with type 1 diabetes for nine years, Omnipod 5 has been life
changing, giving me more freedom to live the way I want to.”
Multiple sensor integrations including Dexcom G6 and Abbott
FreeStyle Libre 2 Plus give prescribers greater flexibility when
recommending a sensor for their patients and make it simple to
begin AID therapy with Omnipod 5. Customers can select the sensor
they would like to connect to Omnipod 5 during the setup
process.
Professor Partha S. Kar, Type 1 Diabetes and Technology Lead at
NHS England and a consultant endocrinologist at Portsmouth
Hospitals NHS Trust said, “The recent integration of Omnipod 5 with
the FreeStyle Libre 2 Plus sensor will allow the life changing
benefits of AID to be brought to many more people throughout the
U.K., and also in the Netherlands. This is an exciting next step on
this incredible journey to simplify life for people with type 1
diabetes.”
To learn more or to get started, visit the Omnipod website.
1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for
60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom
G6 sensor and transmitter are water-resistant and may be submerged
under 2.4 meters (8 feet) of water for up to 24 hours without
failure when properly installed. The FreeStyle Libre 2 Plus sensor
is water-resistant in up to 1 meter (3 feet) of water. Do not
immerse longer than 30 minutes.
2 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with
type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks
standard diabetes therapy followed by three months Omnipod 5 use in
Automated Mode.
3 Brown et al. Diabetes Care (2021). Study in 240 people with
T1D aged 6 - 70 years involving two weeks standard diabetes therapy
followed by three months Omnipod 5 use in Automated Mode.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
disposable Pod provides up to three days of non-stop insulin
delivery, without the need to see or handle a needle. Insulet’s
flagship innovation, the Omnipod 5 Automated Insulin Delivery
System, is a tubeless automated insulin delivery system, integrated
with a continuous glucose monitor to manage blood sugar with no
multiple daily injections, zero fingersticks, and can be fully
controlled by a compatible personal smartphone in the U.S. or by
the Omnipod 5 Controller. Insulet also leverages the unique design
of its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit insulet.com and
omnipod.com.
©2024 Insulet Corporation. Omnipod is a registered trademark of
Insulet Corporation. All rights reserved. The sensor housing,
FreeStyle, Libre, and related brand marks are marks of Abbott and
used with permission. Dexcom is a registered trademark of Dexcom,
Inc. and used with permission. All other trademarks are the
property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620287127/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024